148 related articles for article (PubMed ID: 11870819)
1. Bayesian estimation of the proportion of treatment effect captured by a surrogate marker.
Cowles MK
Stat Med; 2002 Mar; 21(6):811-34. PubMed ID: 11870819
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker.
Bycott PW; Taylor JM
Control Clin Trials; 1998 Dec; 19(6):555-68. PubMed ID: 9875835
[TBL] [Abstract][Full Text] [Related]
3. Design and analysis of Bayesian adaptive crossover trials for evaluating contact lens safety and efficacy.
Zhang Q; Toubouti Y; Carlin BP
Stat Methods Med Res; 2017 Jun; 26(3):1216-1236. PubMed ID: 25698715
[TBL] [Abstract][Full Text] [Related]
4. Surrogate markers and joint models for longitudinal and survival data.
Taylor JM; Wang Y
Control Clin Trials; 2002 Dec; 23(6):626-34. PubMed ID: 12505241
[TBL] [Abstract][Full Text] [Related]
5. Bayesian inference for a nonlinear mixed-effects Tobit model with multivariate skew-t distributions: application to AIDS studies.
Dagne G; Huang Y
Int J Biostat; 2012 Sep; 8(1):. PubMed ID: 22992288
[TBL] [Abstract][Full Text] [Related]
6. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group.
Hughes MD; Daniels MJ; Fischl MA; Kim S; Schooley RT
AIDS; 1998 Oct; 12(14):1823-32. PubMed ID: 9792383
[TBL] [Abstract][Full Text] [Related]
7. Multilevel modelling of clustered grouped survival data using Cox regression model: an application to ART dental restorations.
Wong MC; Lam KF; Lo EC
Stat Med; 2006 Feb; 25(3):447-57. PubMed ID: 16143989
[TBL] [Abstract][Full Text] [Related]
8. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Bayesian expected power via Bayesian bootstrap.
Liu F
Stat Med; 2018 Oct; 37(24):3471-3485. PubMed ID: 29938832
[TBL] [Abstract][Full Text] [Related]
10. Reducing Monte Carlo error in the Bayesian estimation of risk ratios using log-binomial regression models.
Salmerón D; Cano JA; Chirlaque MD
Stat Med; 2015 Aug; 34(19):2755-67. PubMed ID: 25944082
[TBL] [Abstract][Full Text] [Related]
11. Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects.
Pradhan S; Song B; Lee J; Chae JW; Kim KI; Back HM; Han N; Kwon KI; Yun HY
BMC Med Res Methodol; 2017 Dec; 17(1):154. PubMed ID: 29191177
[TBL] [Abstract][Full Text] [Related]
12. Sample size estimation in single-arm clinical trials with multiple testing under frequentist and Bayesian approaches.
Zaslavsky BG; Scott J
J Biopharm Stat; 2012; 22(4):819-35. PubMed ID: 22651117
[TBL] [Abstract][Full Text] [Related]
13. Bayes or bootstrap? A simulation study comparing the performance of Bayesian Markov chain Monte Carlo sampling and bootstrapping in assessing phylogenetic confidence.
Alfaro ME; Zoller S; Lutzoni F
Mol Biol Evol; 2003 Feb; 20(2):255-66. PubMed ID: 12598693
[TBL] [Abstract][Full Text] [Related]
14. A new proportion measure of the treatment effect captured by candidate surrogate endpoints.
Kobayashi F; Kuroki M
Stat Med; 2014 Aug; 33(19):3338-53. PubMed ID: 24782344
[TBL] [Abstract][Full Text] [Related]
15. Data cloning: easy maximum likelihood estimation for complex ecological models using Bayesian Markov chain Monte Carlo methods.
Lele SR; Dennis B; Lutscher F
Ecol Lett; 2007 Jul; 10(7):551-63. PubMed ID: 17542934
[TBL] [Abstract][Full Text] [Related]
16. Bayesian noninferiority test for 2 binomial probabilities as the extension of Fisher exact test.
Doi M; Takahashi F; Kawasaki Y
Stat Med; 2017 Dec; 36(30):4789-4803. PubMed ID: 28960376
[TBL] [Abstract][Full Text] [Related]
17. Evaluating surrogate markers of clinical outcome when measured with error.
Dafni UG; Tsiatis AA
Biometrics; 1998 Dec; 54(4):1445-62. PubMed ID: 9883544
[TBL] [Abstract][Full Text] [Related]
18. Robustness considerations in Bayesian analysis.
Gustafson P
Stat Methods Med Res; 1996 Dec; 5(4):357-73. PubMed ID: 9004378
[TBL] [Abstract][Full Text] [Related]
19. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint.
Zigler CM; Belin TR
Biometrics; 2012 Sep; 68(3):922-32. PubMed ID: 22348277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
